FINWIRES · TerminalLIVE
FINWIRES

Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target

By

Faeth Therapeutics (FTHM) has an average rating of buy and mean price target of $54.40, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Truist Securities Downgrades Sila Realty Trust to Hold From Buy, Raises Price Target to $30 From $28

Truist Securities Downgrades Sila Realty Trust to Hold From Buy, Raises Price Target to $30 From $28

$SILA
Research

Leerink Downgrades Bio-Techne to Market Perform From Outperform, Price Target is $73

Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $70.50, Change: $+11.62, Percent Change: +19.74%

$TECH
Research

Evercore ISI Upgrades Bio-Techne to Outperform From In Line, Adjusts Price Target to $73 From $50

Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TECH